The fibroblast growth factor receptor 2b (FGFR2b)-inhibiting bemarituzumab demonstrated improvements in overall survival and other key secondary end points compared with placebo in first-line gastric cancer.

Dave’s Pharmacy in Alliance, Nebraska, was named the Pharmacy of the Year for cutting-edge patient care.

Independent pharmacy owners Raj Chhadua and Marc Ost are turning to AI-powered tools to streamline operations, improve efficiency, and enhance patient engagement—without sacrificing the personal touch.

Combination therapy with trastuzumab emtansine and trastuzumab significantly enhances survival rates in HER2-positive early breast cancer, outperforming trastuzumab alone.

From vaccine drives and prescriber dinners to YouTube education and automated workflows, these pharmacy owners are finding innovative, hands-on ways to expand services, boost revenue, and stay connected to the communities they serve.

The expanded instructions for use labeling expand on the Farawave and Farawave Nav Pulsed Field Ablation (PFA) catheters.

Arkansas' "shot heard round the pharmacy world": Preventing pharmacy benefit managers from owning pharmacies raises an interesting question for the field.

This designation is significant because there are no FDA-approved treatments for transplant recipients with or preventing antibody-mediated rejection (AMR).

Pharmacy deserts challenge access to essential medications, but innovative solutions like telepharmacy and mobile units empower pharmacists to bridge the gap.

Patients with inflammatory rheumatic diseases may have a protective effect against serious COVID-19 outcomes once they receive a pneumococcal vaccination.

Laura R. Bobolts, PharmD, BCOP, shares actionable strategies for oncology pharmacists to navigate biosimilar and 505(b)(2) drug implementation, manage payer and formulary complexities, and optimize cost-effective care delivery across oncology service lines.

FDA fast-tracks TRE-515 for advanced prostate cancer, combining it with radiation therapy to enhance treatment outcomes and patient care.

Previously indicated to reduce the risk of end-stage kidney disease, cardiovascular death, and hospitalization for heart failure (HF) in chronic kidney disease, finerenone is now approved for patients with HF directly, offering a new treatment option.

Pharmacy-based clinical services demonstrate both public health impact and financial sustainability.

Innovative pharmacist-led care models—from tech-enabled Afib screenings and HPV immunizations to Medicare-supported diabetes prevention—demonstrate how pharmacies are redefining their role in team-based clinical care.

CBD use can elevate liver enzymes in 5% to 6% of adults, highlighting the need for monitoring and safe usage practices.

Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.

States have expanded access to over-the-counter ivermectin, raising concerns among health experts about safety, misinformation, and self-medication risks.

Complete response letters, which indicate reasons why a drug could not be approved in its current form, offer insightful information to drug developers on the inner mechanisms of the FDA’s approval process.

A maternal inflammatory diet during pregnancy raises the risk of offspring developing type 1 diabetes, highlighting the impact of nutrition on early health.

Annie Eisenbeis, PharmD, MBA, showcased how Missouri’s Pharmacy Vaccine Gap Closure Program is transforming pharmacy-based immunization services through scalable workflows, team training, and a redefined role for pharmacy technicians as community health workers.

Lara Zakaria, PharmD, introduced the topic of pharmaconutrition, urging pharmacists to integrate food, lifestyle, and gut health into patient care through evidence-based, practical interventions.

Lumatperone showed a 63% reduction in relapse risk for patients with schizophrenia, promising improved patient stability and care.